Blood based biomarkers beyond genomics for lung cancer screening
Authors:
- 1 June 2018
- journal article
- review article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 7 (3) , 327-335
Abstract
While there is considerable interest at the present time in the development of so-called liquid biopsy approaches for cancer detection based notably on circulating tumor DNA, there are other types of potential biomarkers that show promise for lung cancer screening and early detection. Here we review approaches and some of the promising markers based on proteomics, metabolomics and the immune response to tumor antigens in the form of autoantibodies.Keywords
This publication has 83 references indexed in Scilit:
- EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assaysTumor Biology, 2012
- A Multiplexed Serum Biomarker Immunoassay Panel Discriminates Clinical Lung Cancer Patients from High-Risk Individuals Found to be Cancer-Free by CT ScreeningJournal of Thoracic Oncology, 2012
- Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor ModelsCancer Cell, 2011
- Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control studyBMC Cancer, 2010
- Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung CancerPLOS ONE, 2010
- Clinical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non–Small Cell Lung CancerClinical Cancer Research, 2010
- Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokersBMC Cancer, 2010
- An Expanded Risk Prediction Model for Lung CancerCancer Prevention Research, 2008
- Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancerInternational Journal of Clinical Oncology, 2002